Visual Performance And Defocus Curves Of 4 Leading Full Range Of Vision Iols (Frov) - Galaxy, Clareon Panoptix, Odyssey And Puresee.

The purpose of this study is to evaluate the visual performance and defocus curves of four leading Full Range of Vision (FROV) intraocular lenses (IOLs): Rayner Galaxy, Alcon Clareon Panoptix, Johnson & Johnson Odyssey, and Johnson & Johnson PureSee. We aim to analyze postoperative outcomes at 3 months, including uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), uncorrected intermediate visual acuity (UIVA), distance-corrected intermediate visual acuity (DCIVA), and defocus curves in half diopter steps.

The study is conducted at the eye care center with a specialized cataract surgery unit – reOptis in Poznan, Poland. The patient cohort comprises individuals undergoing cataract surgery with the implantation of one of the four specified FROV IOLs.

A total of 40 patients, 10 for each IOL group, were selected for the study. Each patient was operated on in both eyes with the same lens. Patients underwent phacoemulsification with the implantation of either the Galaxy, Clareon Panoptix, Odyssey, or PureSee IOL. Postoperative follow-ups were conducted at 1 week, 1 and 3 months.

At the 3-month follow-up, visual acuity (VA) measurements are taken for the following VA:

-Uncorrected distance VA (UDVA)

-Corrected DVA (CDVA)

-Uncorrected intermediate VA (UIVA)

-Distance-corrected IVA (DCIVA)

Defocus curves were generated in 0,5 D steps ranging from +1.0 D to -4.0 D to assess the range of vision provided by each IOL. Data were analyzed to compare the visual outcomes and defocus curves among the 4 IOLs

The visual acuity outcomes demonstrate the performance of each IOL in terms of distance, intermediate and near vision. Defocus curve analysis reveals the consistency and range of vision correction provided by each FROV IOL. Detailed statistical analysis is performed to ascertain the significance of differences between the groups.

This study provides valuable insights into the visual performance and defocus profiles of four leading FROV IOLs. The outcomes will help in understanding the benefits and limitations of each IOL, aiding ophthalmologists in making informed decisions for their patients undergoing cataract surgery. Further clinical follow-up and long-term studies are warranted to confirm these findings and optimize the choice of FROV IOLs for diverse patient needs.